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objective. To compare the epidemiology, clinical characteristics, and mortality of patients with bloodstream infections (BSI) caused by
extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) versus ESBL-producing Klebsiella pneumoniae (ESBL-KP) and to
examine the differences in clinical characteristics and outcome between BSIs caused by isolates with CTX-M versus other ESBL genotypes.
methods. As part of the INCREMENT project, 33 tertiary hospitals in 12 countries retrospectively collected data on adult patients diagnosed
with ESBL-EC BSI or ESBL-KP BSI between 2004 and 2013. Risk factors for ESBL-EC versus ESBL-KP BSI and for 30-day mortality were
examined by bivariate analysis followed by multivariable logistic regression.
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results. The study included 909 patients: 687 with ESBL-EC BSI and 222 with ESBL-KP BSI. ESBL genotype by polymerase chain reaction
ampliﬁcation of 286 isolates was available. ESBL-KP BSI was associated with intensive care unit admission, cardiovascular and neurological
comorbidities, length of stay to bacteremia >14 days from admission, and a nonurinary source. Overall, 30-day mortality was signiﬁcantly
higher in patients with ESBL-KP BSI than ESBL-EC BSI (33.7% vs 17.4%; odds ratio, 1.64; P= .016). CTX-M was the most prevalent ESBL
subtype identiﬁed (218 of 286 polymerase chain reaction-tested isolates, 76%). No differences in clinical characteristics or in mortality between
CTX-M and non–CTX-M ESBLs were detected.
conclusions. Clinical characteristics and risk of mortality differ signiﬁcantly between ESBL-EC and ESBL-KP BSI. Therefore, all ESBL-
producing Enterobacteriaceae should not be considered a homogeneous group. No differences in outcomes between genotypes were detected.
clinical trials identiﬁer. ClinicalTrials.gov. Identiﬁer: NCT01764490.
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The spread of extended-spectrum β-lactamase (ESBL)-pro-
ducing Enterobacteriaceae (ESBL-E) is a growing public health
threat worldwide.1 A 2012 study from 72 hospitals in the
United States reported that 16% of Klebsiella pneumoniae and
11.9% of Escherichia coli isolates were ESBL producers.1 Much
higher proportions were found in other populations,2 with
variation between countries and between hospitals. The
limited antibiotic treatment options and adverse clinical
outcomes of infections caused by ESBL-E have raised major
concerns among clinicians and infection control services.3
In the 1980s and 1990s, K. pneumoniae was the pre-
dominant ESBL-E causing nosocomial outbreaks, and TEM
and SHV were the main β-lactamases involved.4,5 In recent
decades, E. coli has surpassed K. pneumoniae, and the most
common β-lactamase is CTX-M.6
Most previous studies that examined the epidemiology and
outcome of infections caused by ESBL-producing organisms
often combined different Enterobacteriaceae to one group
assuming homogeneity; moreover, differences in outcomes
between ESBL genotypes have not been considered.4,7
However, this may not be the case. For example, unlike
ESBL-producing K. pneumoniae (ESBL-KP), ESBL-producing
E. coli (ESBL-EC) is common in community-acquired
infections.6 ESBL-EC has less predilection for hospital trans-
mission than other ESBL-producing species, which has led the
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) to recommend contact precautions for
patients colonized with all ESBL-E except ESBL-EC.8
In this study, our aims were twofold: (1) to compare the
epidemiology, clinical characteristics, and mortality of patients
with bloodstream infections (BSIs) caused by ESBL-EC versus
ESBL-KP; and (2) to examine the differences in clinical
characteristics and outcome between BSIs caused by isolates
with CTX-M versus other ESBL genotypes.
methods
Study Design and Patients
This analysis was part of the INCREMENT project, a retro-
spective cohort study designed to evaluate the epidemiology,
clinical features, treatment efﬁcacy, and prognosis of clinically
signiﬁcant BSI due to ESBL- or carbapenemase-producing
Enterobacteriaceae.9 In total, 33 tertiary-care hospitals in 12
countries participated in the project. For the present study, we
included all adult patients (age> 18 years) with clinically
signiﬁcant, monomicrobial BSIs caused by ESBL-EC or
ESBL-KP from January 2004 through December 2013.
Variables and Deﬁnitions
Patient data were collected from hospital medical charts and
included the following: demographic characteristics, ward type,
site of acquisition (nosocomial, healthcare-associated or com-
munity), length of stay to bacteremia, source of infection (eg,
urinary, biliary), comorbidities (individually and by Charlson
score, dichotomized as ≤2 or > 2),10 severity of underlying illness
as measured by McCabe classiﬁcation,11 severity of BSI (presence
of severe sepsis or septic shock and Pitt bacteremia score
dichotomized as ≤4 or > 4),12 organism and resistance genotype,
and 30-day mortality (calculated from the day of the ﬁrst positive
blood culture was taken). For patients who were no longer hos-
pitalized at 30 days, we determined mortality by telephoning
patients or their relatives and by consulting mortality registers.
Infections were deﬁned as nosocomial if symptoms began
> 48 hours after hospital admission or within 48 hours of
hospital discharge. Infections were deﬁned as healthcare-
associated if they were not nosocomial and if, in the previous
3 months, the patient was hospitalized in an acute-care
hospital, long-term care facility or day hospital, had undergone
dialysis, surgery or other invasive procedure, or received
specialized home care. Patients who were neither nosocomial
nor healthcare associated were considered strictly community
acquired. The deﬁnitions of the Centers for Disease Control
and Prevention (CDC) for nosocomial infections were used to
classify the primary source of infection.13 Antimicrobial ther-
apy was considered appropriate when including at least 1 drug
active in vitro against the causative bacteria.
Laboratory Methods
Enterobacteriaceae strains were identiﬁed using standard
microbiological techniques in each participating center. ESBL
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production and susceptibility to given antibiotics were
screened and conﬁrmed according to the guidelines of the
Clinical and Laboratory Standards Institute (CLSI).14 For
some isolates, the ESBL genes had been characterized by
polymerase chain reaction (PCR)8 according to the needs of
the local laboratories; no criteria were speciﬁed for the
selection of the isolates. For secondary BSI, the source
(eg, urine, wound) did not need to be microbiologically
conﬁrmed if enough clinical criteria were present.
Statistical Analysis
Risk factors for ESBL-EC versus ESBL-KP BSI and for death
were initially examined by bivariate analysis. Categorical
variables were compared using the χ2 test, and continuous
variables were compered using the t test. Variables with
P< 0.10 were included in a multivariable logistic model. In
addition, we decided a priori to include age and sex in the
multivariable model. In the multivariate logistic model,
P< 0.05 was considered statistically signiﬁcant.
SPSS version 22.0 software (SPSS, Chicago, IL) and SAS
version 9.4 software (SAS Institute, Cary, NC) were used for
this analysis.
Ethics
The Spanish Agency of Medicines and the Hospital Uni-
versitario Virgen Macarena Institutional Review Board
approved the INCREMENT project. The need for written
informed consent was waived. Approvals were also obtained
from the institutional review boards of all participating centers.
results
Our sample included 909 patients: 687 (75%) with ESBL-EC
and 222 (25%) with ESBL-KP BSI. The contributing institutes
and the number of cases contributed by each center are sum-
marized in Supplementary Table 1. The median age was 69
years (interquartile range [IQR], 56–79 years), and 55% of the
patients were male. Only 149 patients (16%) had a strictly
community-acquired infection. The median length of stay to
bacteremia from admission was 1 day (IQR, 0–11 days). The
urinary tract was the most common source of BSI (397
patients, 44%), followed by intra-abdominal infection (106,
12%) and the biliary system (104, 11%). Moreover, 44% of
patients had a high Charlson comorbidity index (>2); 12.5%
had a high Pitt bacteremia score (>4); and 35.5% developed
severe sepsis or septic shock.
Risk Factors for BSI Caused by ESBL-EC Versus ESBL-KP
Table 1 compares epidemiological and clinical characteristics
between patients with ESBL-EC BSI and ESBL-KP BSI. In
bivariate analysis, patients with ESBL-KP were more likely to
have cardiovascular, neurologic, or renal disease, and they
were more likely to be in the ICU at the time of BSI diagnosis,
to have a nosocomial BSI, and to have developed bacteremia
>14 days after admission. A urinary source was more common
in patients with ESBL-EC BSI. In the multivariable model,
ESBL-KP BSI was independently associated with ICU admis-
sion, cardiovascular disease, neurological disease, later onset of
bacteremia, and a nonurinary source.
In a subgroup analysis of 423 patients with nosocomial BSI,
the same 5 risk factors were signiﬁcant in a multivariable
model (data not shown). No signiﬁcant risk factors were found
for patients with healthcare-associated community acquisi-
tion. Subgroup analysis of patients with strict community
acquisition was not done due to small number of patients
(21 patients with ESBL-KP).
Thirty-Day Mortality Following ESBL-EC Versus ESBL-KP
BSI
The 30-day mortality rate was higher among patients with
ESBL-KP BSI than with ESBL-EC BSI (33.7% vs 17.4%).
Differences in mortality risk factors between ESBL-EC and
ESBL-KP BSI are summarized in Table 2A and 2B. Septic shock/
severe sepsis, bad prognosis according to McCabe classiﬁcation,
and inappropriate targeted therapy were risk factors for mor-
tality in both ESBL-EC and ESBL-KP. Other risk factors for
mortality, age and nonurinary source, were signiﬁcant only in
ESBL-EC. However, the odds ratios (ORs) exhibited a similar
trend in ESBL-KP but did not reach statistical signiﬁcance due
to the smaller cohort. ESBL-KP remained an independent pre-
dictor of 30-day mortality (OR, 1.64; 95% conﬁdence interval
[CI], 1.1–2.5). In the healthcare-associated community-acqui-
sition subgroup, mortality rates were also signiﬁcantly higher in
ESBL-KP versus ESBL-EC (27% vs 14%; P= .0125).
Differences in Clinical Characteristics and Outcome by ESBL
Genotype
A total of 286 bacterial isolates (218 EC and 68 KP) underwent
PCR ampliﬁcation of bla ESBL genes. No signiﬁcant differences
were found between patients whose isolates had and had not
their ESBL genes characterized in terms of demographics,
underlying conditions, bacterial species, sources of infection,
severity of infection, or mortality (data not shown). CTX-M was
the most prevalent ESBL subtype identiﬁed (218, 76%), both in
E. coli (78%) and in K. pneumoniae (69%). The other ESBL
genotypes present in our sample were SHV and TEM (22% of
E. coli and 31% of K. pneumoniae). Table 3 compares clinical
characteristics and outcomes in patients with BSI caused by
bacteria producing CTX-M versus other ESBL enzymes. In
bivariate analysis, non–CTX-M was signiﬁcantly associated with
pulmonary, cardiovascular, neurological, and connective tissue
disease and with total Charlson score >2. We did not ﬁnd sig-
niﬁcant differences in clinical severity of the BSI, site of acquisi-
tion, or mortality rate between CTX-M and non–CTX-M ESBLs.
Of the 68 patients, 13 (19%) with non–CTX-M were strictly
community acquired compared with 30 of 218 patients with
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CTX-M (14%; P= .28). In addition, 10 patients (n= 13) were
from a single center, which might reﬂect local epidemiology
and not a general trend.
discussion
In this large cohort of patients with ESBL-E BSI, we found
differences between patient characteristics, clinical presenta-
tion, and outcome, depending on whether the causative
organism was for ESBL-EC or ESBL-KP. Bacteremia due to
ESBL-KP was more often of nonurinary origin, occurred later
during hospitalization, was associated with comorbidities
(cardiovascular and neurological) and had a more severe
clinical presentation. Bacteremia due to ESBL-EC tended to
occur more often upon admission (community onset) and to
have a urinary source. Our results are in accordance with a
previous study by Freeman et al15 who demonstrated differ-
ences in risk proﬁles and clinical characteristics between
patients with ESBL-EC BSI (eg, community-acquired infec-
tions) and patients with ESBL-KP BSI (eg, ICU admission).15
table 1. Demographic and Clinical Characteristics of Patients With ESBL-EC and ESBL-KP Bloodstream Infectiona
Covariate
ESBL-EC
(N= 687), No. (%)
ESBL-KP
(N= 222), No. (%) Crude OR P Value
OR
Multivariate
(95% CI)b P Value
Demographics
Sex Male 370 (54) 134 (60) 1.305 .09
Female 317 (46) 88 (40)
Age, medan y (IQR) 69 (56–79) 70 (59–79) 1.003 .509
Site of acquisition
Nosocomial 284 (42) 139 (63) 2.349 <.001 1.391
(0.929–2.081)
.109
Community 383 (58) 80 (37)
Strictly community 128 (36) 21 (27) .12
Community-
healthcare- associated
230 (64) 58 (73)
Epidemiological parameters
Source Urinary tract 327 (48) 70 (32) 0.507 <.001 0.596
(0.416–0.854)
.005
Other 360 (52) 152 (68)
Ward type Emergency dept. 219 (32) 21 (15)
Medical ward 316 (46) 97 (45)
Surgical ward 92 (14) 39 (18)
ICU 56 (8) 47 (22) 3.151 <.001 2.303
(1.45–3.65)
<.001
Unknown 22
LOS to bacteremia 0–14 days 575 (84) 150 (68) 2.464 <.001 1.703
(1.1–2.639)
.017
>14 days 112 (16) 72 (32)
Clinical characteristics and comorbidity
Cardiovascular disease 137 (20) 81 (36.5) 2.306 <.001 2.187
(1.527–3.13)
<.001
Neurologic disease 83 (12) 41 (18) 1.623 .02 1.618
(1.032–2.537)
.036
Pulmonary disease 115 (17) 45 (20) .25
Renal disease 127 (19) 58 (27) 1.559 .015
Liver disease 89 (13) 25 (11) .43
Inﬂammatory bowel disease 37 (5.6) 5 (2) 0.398 .049
Malignancy 262 (40) 80 (37) .526
HIV positive 14 (2) 2 (0.9) .26
Charlson comorbidity
score
≤2 286 (41.6) 107 (48) 1.305 .086
> 2 401 (58) 115 (52)
McCabe classiﬁcation Nonfatal 337 (51) 109 (51) .867
Death w/i 1 yc 226 (34) 77 (36)
Death w/i 5 yc 97 (15) 29 (13)
Pitt score ≤4 657 (96) 202 (91) 2.168 .008
>4 30 (4) 20 (9)
Severe sepsis/septic shock 227 (34) 96 (44) 1.54 .007
NOTE. ESBL, extended-spectrum β-lactamase; EC, Escherichia coli; KP, Klebsiella pneumoniae; IQR, interquartile range; OR, odds ratio;
ICU, intensive care unit; HIV, human immunodeﬁciency virus; LOS, length of stay.
aPercentage of persons with known data.
bOdds ratio (OR) is for ESBL-KP infection.
cDeath expected within 1 year or 5 years, as indicated.
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Gram-negative bacillary sepsis with shock has a mortality
rate of 12%–38%.2,16 In our cohort, the 30-day mortality rate
was 21.4% and was signiﬁcantly higher for ESBL-KP BSI
(33.7%) than for ESBL-EC BSI (17.4%). We found that
bacterial species is among the most important determinants of
the risk for mortality. A study conducted in Finland likewise
found higher 28-day mortality in patients with nosocomial BSI
caused by ESBL-KP (28.0%) than by ESBL-EC (14.8%).2 In
contrast, Leistner et al16 did not ﬁnd a difference in in-hospital
mortality between BSI caused by ESBL-KP and ESBL-EC,
although they did ﬁnd signiﬁcantly higher mortality with
ESBL-negative KP than with ESBL-negative EC.
table 2. Risk Factors for 30-Day Mortality in Patients With ESBL-EC (TABLE 2A) and ESBL-KP (TABLE 2B ) Bloodstream Infection by
Univariate and Multivariate Analyses
TABLE 2A
Parameter
No Mortality
(n= 567),
No. (%)
30-Day Mortality
(n= 120),
No. (%) Crude OR P Value
ORMultivariate
(95% CI)a P Value
Male sex 303 (53) 67 (56) 1.101 .633 1.08
(2.309–0.742)
.352
Age, median y (IQR) 68 (55–79) 73 (60–79) 1.016 .012 1.042
(1.020–1.064)
<.001
Site of acquisition Nosocomial 221 (40) 63 (55) 1.820 .003 1.160
(0.586–2.296)
.671
Community 332 (60) 52 (45)
Source Urine 295 (52) 32 (27) 0.330 <.001 0.316
(0.165–0.608)
<.001
Other 272 (48) 88 (73)
Appropriate empirical therapy No 257 (45) 75 (62) 0.497 <.001 0.841
(0.422–1.677)
.623
Yes 310 (55) 45 (33)
Appropriate targeted therapy No 69 (12) 53 (44) 0.175 <.001 0.202
(0.093–0.439)
<.001
Yes 498 (88) 67 (56)
Length of stay to bacteremia 0–14 days 483 (85) 92 (77) 1.75 .022 1.384
(0.609–3.145)
.438
>14 days 84 (15) 28 (23)
ICU 37 (7) 19 (16) 2.706 <.001 2.188
(0.923–5.187)
.075
Cardiovascular disease 106 (19) 32 (27) 1.581 .048
Neurologic disease 65 (11) 18 (15) 1.363 .280
Pulmonary disease 82 (15) 33 (29) 2.331 <.001
Diabetes mellitus 179 (32) 43 (37) 1.267 .265
Connective tissue disorder 16 (3) 4 (4) 1.245 .699
Inﬂammatory bowel disease 28 (5) 9 (8) 1.638 .211
Liver disease 71 (13) 18 (16) 1.294 .367
Renal disease 102 (19) 25 (22) 1.212 .444
Malignancy 204 (37) 58 (51) 1.778 .005 1.047
(0.514–2.132)
.898
HIV positive 12 (2) 2 (2) 0.808 .782
Charlson comorbidity index ≤2 347 (61) 54 (45) 1.928 .001 1.275
(0.694–2.343)
.434
>2 220 (39) 66 (55)
McCabe classiﬁcation Nonfatal 305 (56) 32 (28) <.001 .001
5 years 182 (33) 44 (38) 1.950
(0.974–3.903)
1 year 58 (11) 39 (34) 5.501
(2.185–13.849)
Global Pitt score ≤4 559 (99) 98 (82) 15.686 <.001 5.214
(1.377–19.740)
.151
>4 8 (1) 22 (18)
Severe sepsis/shock 140 (26) 87 (74) 8.431 <.001 6.724
(3.740–12.090)
<.001
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Here, CTX-M was the most prevalent type of ESBL in our
sample, as in other studies.16 There was no signiﬁcant asso-
ciation between the type of ESBL (CTX-M vs non–CTX-M)
and the organism or between the type of ESBL and whether the
infection was nosocomial. These ﬁndings are consistent with
previous data.17
Epidemiologically, it has been suggested that CTM-X
β-lactamase has higher rates of community transmission and
an association with E. coli.17 Our data support studies
indicating that CTX-M is also prevalent in ESBL-KP.18 We
found that non–CTX-M was associated with pulmonary,
cardiovascular, neurological, and connective-tissue diseases.
TABLE 2B.
Parameter
No Mortality
(n= 147),
No. (%)
30-Day Mortality
(n= 75),
No. (%) Crude OR P Value
ORMultivariate
(95% CI)a P Value
Male sex 90 (61) 44 (59%) 0.899 .712 0.731
(0.661–1.615)
.424
Age, median y (IQR) 71 (55–79) 68 (61–76) 1.003 .785 1.010
(0.983–1.037)
.481
Site of acquisition Nosocomial 83 (58) 56 (75) 2.16 .013 1.292
(0.552–3.028)
.555
Community 61 (42) 19 (25)
Source Urine 55 (37) 15 (20) 0.43 .008 0.609
(0.254–1.462)
.267
Other 92 (63) 60 (80)
Appropriate Empirical Therapy No 75 (51) 37 (49) 1.07 .81
Yes 72 (49) 38 (51)
Appropriate Targeted Therapy No 25 (17) 23 (31) 0.46 .019 0.345
(0.145–0.822)
.016
Yes 122 (83) 52 (69)
Length of stay to bacteraemia 0–14 d 104 (71) 46 (61) 1.52 .16
>14 d 43 (29) 29 (39)
ICU 20 (14) 27 (37) 3.55 <.001 1.425
(0.510–3.980)
.499
Cardiovascular disease 52 (35) 29 (39) 1.15 .629
Neurologic disease 27 (18) 14 (18) 1.02 .956
Pulmonary disease 30 (21) 15 (20) 0.95 .88
Diabetes mellitus 50 (35) 31 (42) 1.402 .25
Connective tissue disorder 4 (3) 3 (4) 1.44 .69
Inﬂammatory bowel disease 4 (3) 1 (1) 0.48 .66
Liver disease 17 (12) 8 (11) 0.899 .815
Renal disease 34 (24) 24 (33) 1.57 .153
Malignancy 57 (40) 23 (32) 0.686 .215
HIV positive 1 (1) 1 (1) 1.959 .630
Charlson comorbidity index ≤2 82 (56) 33 (44) 1.606 .096 1.389
(0.614–3.140)
.430
>2 65 (44) 42 (56)
McCabe classiﬁcation Nonfatal 82 (57) 27 (37) <.001 .022
5 years 10 (7) 19 (26) 1.553
(0.640–3.770)
1 year 50 (37) 27 (37) 5.567
(1.638–18.927)
Global Pitt score ≤4 143 (97) 59 (79) 9.69 <.001 3.949
(0.983–15.870)
.053
>4 4 (3) 16 (21)
Severe sepsis/shock 42 (30) 54 (72) 6.06 <.001 4.270
(1.952–9.339)
<.001
NOTE. ESBL, extended-spectrum β-lactamase; EC, Escherichia coli; KP, Klebsiella pneumoniae; OR, odds ratio; ICU, intensive care unit;
HIV, human immunodeﬁciency virus.
aOR is for ESBL-KP infection.
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It was also associated with total Charlson score >2, which may
suggest that these patients’ infections were more healthcare
associated. We conclude that, today, both ESBL-EC and
ESBL-KP contain the CTX-M and non–CTX-M subtypes
and that infections with all ESBL genotypes can occur in the
community and in the hospital settings.
Our study has several strengths. The data were acquired
from different hospitals in several countries, and the sample
size was large. However, this study also has several limitations.
The retrospective design of the study could be subject to
information bias. However, we believe that the large number
of patients included at least partly overcomes this problem.
We analyzed the data from all countries together,
but the epidemiology of ESBL genotypes may vary between
countries. The ESBL genes were only characterized by PCR in a
subgroup of isolates; however, the features of these
patients were similar to those for which the ESBL gene were
not studied.
In conclusion, the epidemiology, clinical characteristics, and
risk of mortality differ signiﬁcantly between ESBL-EC and
ESBL-KP, and these factors do not differ by ESBL genotype.
Therefore, we recommend that ESBL-E should not be
considered a homogenous group. In addition to the different
epidemiology of the bacteria, the clinical course differs; thus,
different treatment options may be needed. Further studies
should focus on individual bacteria and not on ESBL-E as
a group.
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